Short answer
Xencor Inc (XNCR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026 announced by Xencor.
Xencor Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced by Xencor
- Financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $51.2M, up from $43.6M, boosted by $27.6M recognized from the Alexion royalty settlement
- Additional Alexion settlement consideration $77.4M expected in Q3, providing near-term cash and revenue support
- R&D expense rose to $71.9M from $61.7M, reflecting accelerated investment across the clinical pipeline
- Net loss narrowed to $21.7M, or $0.29 per share, from $30.8M, or $0.41 per share
- Cash and marketable debt securities $486.4M, with year-end guidance of $420M-$440M and runway through 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xencor Inc 8-K filings
Get the next XNCR 8-K as it lands
Follow XNCR for push alerts, or ask the research agent what this filing means.